LeMaitre reported preliminary third-quarter 2026 sales of $68.0 million, up 11% from a year earlier, while diluted EPS fell 14% to $0.65 and operating income fell 13% to $17.7 million. The company kept its full-year 2026 outlook, guiding to sales of $274.8 million to $276.8 million and EPS of $2.77 to $2.82, and declared a $0.25 quarterly dividend. The company also bought certain vascular assets from B. Braun for $19.2 million in October.
Q3 2026 net sales $68.0 million, up 11% (12% organic) from Q3 2025; diluted EPS $0.65 versus $0.75
Q3 operating income $17.7 million versus $20.3 million a year earlier; the prior-year period included a $3.4 million employee retention tax credit benefit
FY 2026 guidance: sales $274.8 million to $276.8 million and EPS $2.77 to $2.82; Q4 EPS guidance $0.70 to $0.75
Quarterly dividend of $0.25 per share payable December 3, 2026, to holders of record on November 19, 2026
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From LeMaitre Vascular's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$249.60M
+13.5%
$2.52
+30.6%
23.1%
FY2024
$219.86M
+13.6%
$1.93
+44.0%
20.0%
FY2023
$193.48M
+19.7%
$1.34
+44.1%
15.6%
FY2022
$161.65M
+4.7%
$0.93
-25.6%
12.8%
FY2021
$154.42M
+19.4%
$1.25
+20.2%
17.4%
Frequently asked questions
When is LeMaitre Vascular's next earnings date?
LeMaitre Vascular has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did LeMaitre Vascular earn last quarter?
For the quarter ended Sep 2026, LeMaitre Vascular reported diluted EPS of $0.65 (-13.3% year over year) on revenue of $67.97M (+11.3%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.